TABLE 2.

AUC of CSF biomarkers.

	Ng	T-tau	P-tau	Ng+ T-tau	Ng+ P-tau	Ng+ T-tau+ P-tau
CN ε4+	0.613 (0.443–0.782) (p = 0.170)	0.624 (0.450–0.799) (p = 0.130)	0.672 (0.516–0.827) (p = 0.037)	0.626 (0.453–0.800) (p = 0.124)	0.669 (0.513–0.825) (p = 0.039)	0.718 (0.578–0.859) (p = 0.008)
MCI ε4–	0.585 (0.469–0.700) (p = 0.148)	0.606 (0.493–0.720) (p = 0.070)	0.613 (0.498–0.724) (p = 0.058)	0.600 (0.486–0.715) (p = 0.087)	0.612 (0.500–0.725) (p = 0.055)	0.603 (0.489–0.717) (p = 0.078)
MCI ε4+	0.808 (0.730–0.887) (p < 0.001)	0.875 (0.812–0.937) (p < 0.001)	0.881 (0.819–0.943) (p < 0.001)	0.876 (0.814–0.938) (p < 0.001)	0.881 (0.820–0.942) (p < 0.001)	0.881 (0.820–0.942) (p < 0.001)
AD ε4–	0.809 (0.676–0.941) (p < 0.001)	0.827 (0.686–0.968) (p < 0.001)	0.824 (0.677–0.970) (p < 0.001)	0.825 (0.683–0.967) (p < 0.001)	0.819 (0.672–0.965) (p < 0.001)	0.833 (0.699–0.968) (p < 0.001)
AD ε4+	0.783 (0.687–0.878) (p < 0.001)	0.879 (0.809–0.949) (p < 0.001)	0.888 (0.821–0.955) (p < 0.001)	0.880 (0.811–0.949) (p < 0.001)	0.889 (0.822–0.956) (p < 0.001)	0.888 (0.821–0.956) (p < 0.001)

AUC, area under the receiver operator characteristics curve; Ng, neurogranin; T-tau, total-tau; P-tau, phosphorylated-tau at threonine 181; CN, cognitively normal; MCI, mild cognitive impairment; AD, Alzheimer’s disease.